Indeed, we and others have shown that sensitivity to AKT inhibitors was observed in both PIK3CA-mutant/PTEN-wild-type and PIK3CA-wild-type/PTEN-null breast cancer cell lines, and sensitivity to AKT inhibitors correlated with SGK and p-AKT expression levels [72,73,74,75]. This evidence concerns the gene PIK3CA and breast carcinoma.